Top News
Latest News
MARKET TRENDS
7 Aug 2025
Gene Editing’s Next Battle: Cracking the Delivery CodeINVESTMENT
30 Jul 2025
Lilly Bets $1.3B on One-Shot Cure for Heart DiseaseTECHNOLOGY
16 Jul 2025
AI and CRISPR: A Partnership Set to Rewrite BiotechPARTNERSHIPS
10 Jul 2025
AbbVie Goes All In on In-Body Gene Therapy
One Injection, Decades of Heart Protection?
RESEARCH
4 Jul 2025
CRISPR therapy cuts LDL by 86% in a single dose, hinting at a future where gene editing replaces daily heart meds.
MARKET TRENDS
7 Aug 2025
Gene Editing’s Next Battle: Cracking the Delivery Code
Biotech firms like Intellia and Editas race to crack CRISPR delivery, a key to market dominance and future gene therapy breakthroughs.
INVESTMENT
30 Jul 2025
Lilly Bets $1.3B on One-Shot Cure for Heart Disease
Lilly buys Verve Therapeutics to chase a one-time gene edit that could end lifelong cholesterol treatment.
TECHNOLOGY
16 Jul 2025
AI and CRISPR: A Partnership Set to Rewrite Biotech
AI is reshaping how CRISPR therapies reach cells, cutting delays and boosting safety in the race for next-gen gene editing.
PARTNERSHIPS
10 Jul 2025
AbbVie Goes All In on In-Body Gene Therapy
AbbVie acquires Capstan to unlock in-vivo gene delivery and transform autoimmune treatment with faster, easier therapies.
RESEARCH
4 Jul 2025
One Injection, Decades of Heart Protection?
CRISPR therapy cuts LDL by 86% in a single dose, hinting at a future where gene editing replaces daily heart meds.
INNOVATION
24 Jun 2025
One-Shot CRISPR Could Rewrite Blood Disorder Care
Editas’ single-dose CRISPR therapy could make sickle cell treatment faster, cheaper, and far more accessible.
SUBSCRIBE FOR UPDATES
By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.